BTG **Sentry**



PROTECTION WHEN YOU NEED IT, PATENCY WHEN YOU DON'T

RE-INVENTING PE PROTECTION

The BTG Sentry Bioconvertible IVC Filter is designed to provide immediate protection[1] against Pulmonary Embolism (PE) in patients at transient risk of PE. The BTG Sentry is designed to bioconvert following that risk period, to leave a patent, unobstructed lumen[1], eliminating the need for retrieval procedures, as well as reducing the associated risks and complications[1] of conventional long-term filters[1].



BTGVascular.com

SETTING THE STANDARD FOR VASCULAR THERAPIES

VASCULAR | BTG

BTG Sentry IVC Filter (NM60-16-28) System Components

- Bioconvertible IVC Filter
- Introducer Sheath
- Dilator
- Pusher
- Loading Tool

Product Specifications

- Indicated for IVCs with average diameters between 16 mm and 28 mm
- Maximum deployed length is 57.7 mm
- Designed for access via left or right femoral vein, or right jugular vein
- Delivered through a 7 Fr ID Introducer Sheath

Non-clinical testing has demonstrated that the filter is MR conditional, and can be scanned under the following conditions[18]

- Static magnetic field of 1.5 T or 3.0 T
- Spatial gradient field of 40 T/m or 4,000 G/cm or less
- Maximum whole body averaged specific absorption rate of:
  - 2.0 W/kg at 1.5 T
  - 1.0 W/kg at 3.0 T



Unique Frame

- Cylindrical Nitinol frame designed to minimize migration, perforation, embolization, and tilt
- Self-expanding filter cone formed by 6 arms held centrally by a bioabsorbable filament[2]
- Self-centering filtering cone is designed to reduce the risk of tilting and thereby maximizes filtration capacity

Bioconvertible Design

- Designed to automatically bioconvert with arms retracting to the IVC wall after the period of transient risk (approximately 60 days)[1], providing protection when you need it[3-16]
- Eliminates the requirement, costs, and risks associated with IVC filter retrieval

Proven Results

- The prospective multicenter SENTRY study demonstrated a high level of safety and effectiveness
- The trial established 100% freedom from new symptomatic PEs through 12 months, while typical published rates of symptomatic PEs range from 0.5 – 6%[17]

SENTRY IVC Filter Trial

Results	**0 – 1 month (n = 129)**	**1 – 2 months (n = 127)**	**2 – 6 months (n = 126)**	**6 – 12 months (n = 117)**	**12 – 24 months (n = 85)**[19,20]
New Symptomatic PE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Stability Complications	**1 month (n = 129)**	**2 months (n = 119)**	**6 months (n = 114)**	**12 months (n = 111)**	**24 months (n = 85)**[19]
Tilt	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Migration	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Fracture	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
IVC Perforation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Any Complication Found on Imaging	**0 (0%)**	**0 (0%)**	**0 (0%)**	**0 (0%)**	**0 (0%)**

[1] Dake M. J. Vasc Interv Radiol 2018; 05.009, Las Vegas, NV, September 2017. [2] Composed of Poly p-dioxanone (PPDO). [3] Brackenridge. *Am. J. Surg. 2011;* 201, 209 – 215 [4] Batty. *ANZ. J. Surg. 2012*; 82, 817–821 [5] Sing. *J. Trauma 2016*; 60, 732 – 735. [6] Coleman. *J. Am. Coll. Surg. 2015*; 220, 731 – 736. [7] Parvizi. *J. Arthroplasty 2015*; 30: 1,050 – 1,053. [8] Bjørnarå. *J. Bone Joint Surg. Br. 2006*; 88: 386 – 391. [9] Arcelus. *Thromb. Haemost. 2008*; 99: 546 – 551. [10] White. *Arch. Intern. Med. 1998*; 158: 1,525 – 1,531. [11] Hope. *Am. J. Surg. 2007*; 194, 814 – 819. [12] Douketis. *Arch. Intern. Med. 2000*; 160, 3,431 – 3,436. [13] Kearon. *CHEST J. 2016*; 149, 315 – 352. [14] Owings. *Arch. Surg. 1997*; 132: 862 – 867. [15] Spencer Netto. *Injury 2012*; 43: 1,502 – 1,506. [16] SooHoo. *J. Arthroplasty 2006*; 21: 705 – 711. [17] Caplin. *J. Vasc Interv. Radiol. 2011*; 22, 1,499 – 1,506. [18] See IFU for complete MR Conditional Information. [19] Dake, M., SENTRY Trail 2-year Update, VIVA Symposium, Nov 2018 [20] Refers to new symptomatic PEs that were determined to be "device related" by the CEC. There were 2 new symptomatic PEs between 12 and 24 months that were adjudicated by the CEC as not device related.

Product availability varies by country. Prior to use, please refer to the applicable Instructions for Use (IFU) for complete product indications, contraindications, warnings, and precautions.
Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician.

BTG Vascular | 11911 N. Creek Pkwy S. | Bothell, WA 98011 | 888.400.3567